Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Leighl, NB; Paz-Ares, L; Douillard, JY; Peschel, C; Arnold, A; Depierre, A; Santoro, A; Betticher, DC; Gatzemeier, U; Jassem, J; Crawford, J; Tu, D; Bezjak, A; Humphrey, JS; Voi, M; Galbraith, S; Hann, K; Seymour, L; Shepherd, FA 
Titel:
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 
Abstract:
PURPOSE: To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non-small-cell lung cancer (NSCLC). In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB/IV NSCLC, performance status (PS) 0 to 2, and adequate organ function were eligible. All patients received paclitaxel 200 m...    »
 
Zeitschriftentitel:
J Clin Oncol 
Jahr:
2005 
Band / Volume:
23 
Heft / Issue:
12 
Seitenangaben Beitrag:
2831-9 
Sprache:
eng 
Print-ISSN:
0732-183X 
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik